Browsing Tag
Virginia Cancer Specialists
2 posts
AVCT near 52-week high as Avacta doses first patient in AVA6103 Phase 1 trial
Avacta (AVCT) has treated the first patient in the FOCUS-01 Phase 1 trial of AVA6103, its Gen Two pre|CISION exatecan PDC. Initial data expected late 2026. Read more.
Avacta (AIM: AVCT) opens AVA6103 Phase 1: Can sustained-release engineering salvage exatecan’s clinical legacy?
Avacta Therapeutics opens Phase 1 enrollment for AVA6103 exatecan PDC at two US oncology centers. Early data expected H2 2026. Read what it means for AVCT investors.